Literature DB >> 30526008

Variance prior specification for a basket trial design using Bayesian hierarchical modeling.

Kristen M Cunanan1, Alexia Iasonos1, Ronglai Shen1, Mithat Gönen1.   

Abstract

BACKGROUND: In the era of targeted therapies, clinical trials in oncology are rapidly evolving, wherein patients from multiple diseases are now enrolled and treated according to their genomic mutation(s). In such trials, known as basket trials, the different disease cohorts form the different baskets for inference. Several approaches have been proposed in the literature to efficiently use information from all baskets while simultaneously screening to find individual baskets where the drug works. Most proposed methods are developed in a Bayesian paradigm that requires specifying a prior distribution for a variance parameter, which controls the degree to which information is shared across baskets.
METHODS: A common approach used to capture the correlated binary endpoints across baskets is Bayesian hierarchical modeling. We evaluate a Bayesian adaptive design in the context of a non-randomized basket trial and investigate three popular prior specifications: an inverse-gamma prior on the basket-level variance, a uniform prior and half-t prior on the basket-level standard deviation.
RESULTS: From our simulation study, we can see that the inverse-gamma prior is highly sensitive to the input hyperparameters. When the prior mean value of the variance parameter is set to be near zero (≤0.5) , this can lead to unacceptably high false-positive rates (≥40%) in some scenarios. Thus, use of this prior requires a fully comprehensive sensitivity analysis before implementation. Alternatively, we see that a prior that places sufficient mass in the tail, such as the uniform or half-t prior, displays desirable and robust operating characteristics over a wide range of prior specifications, with the caveat that the upper bound of the uniform prior and the scale parameter of the half-t prior must be larger than 1.
CONCLUSION: Based on the simulation results, we recommend that those involved in designing basket trials that implement hierarchical modeling avoid using a prior distribution that places a majority of the density mass near zero for the variance parameter. Priors with this property force the model to share information regardless of the true efficacy configuration of the baskets. Many commonly used inverse-gamma prior specifications have this undesirable property. We recommend to instead consider the more robust uniform prior or half-t prior on the standard deviation.

Entities:  

Keywords:  Basket trial; Bayesian method; adaptive design; phase II; variance prior

Mesh:

Year:  2018        PMID: 30526008      PMCID: PMC6822679          DOI: 10.1177/1740774518812779

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  14 in total

1.  Robust exchangeability designs for early phase clinical trials with multiple strata.

Authors:  Beat Neuenschwander; Simon Wandel; Satrajit Roychoudhury; Stuart Bailey
Journal:  Pharm Stat       Date:  2015-12-18       Impact factor: 1.894

2.  Bayesian Baskets: A Novel Design for Biomarker-Based Clinical Trials.

Authors:  Lorenzo Trippa; Brian Michael Alexander
Journal:  J Clin Oncol       Date:  2017-01-03       Impact factor: 44.544

3.  Bayesian response-adaptive designs for basket trials.

Authors:  Steffen Ventz; William T Barry; Giovanni Parmigiani; Lorenzo Trippa
Journal:  Biometrics       Date:  2017-02-17       Impact factor: 2.571

4.  Increasing the efficiency of oncology basket trials using a Bayesian approach.

Authors:  Rong Liu; Zheyu Liu; Mercedeh Ghadessi; Richardus Vonk
Journal:  Contemp Clin Trials       Date:  2017-06-16       Impact factor: 2.226

5.  The Bayesian basket design for genomic variant-driven phase II trials.

Authors:  Richard Simon; Susan Geyer; Jyothi Subramanian; Sameek Roychowdhury
Journal:  Semin Oncol       Date:  2016-01-18       Impact factor: 4.929

6.  AKT Inhibition in Solid Tumors With AKT1 Mutations.

Authors:  David M Hyman; Lillian M Smyth; Mark T A Donoghue; Shannon N Westin; Philippe L Bedard; Emma J Dean; Hideaki Bando; Anthony B El-Khoueiry; José A Pérez-Fidalgo; Alain Mita; Jan H M Schellens; Matthew T Chang; Jonathan B Reichel; Nancy Bouvier; S Duygu Selcuklu; Tara E Soumerai; Jean Torrisi; Joseph P Erinjeri; Helen Ambrose; J Carl Barrett; Brian Dougherty; Andrew Foxley; Justin P O Lindemann; Robert McEwen; Martin Pass; Gaia Schiavon; Michael F Berger; Sarat Chandarlapaty; David B Solit; Udai Banerji; José Baselga; Barry S Taylor
Journal:  J Clin Oncol       Date:  2017-05-10       Impact factor: 44.544

7.  Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

Authors:  John D Hainsworth; Funda Meric-Bernstam; Charles Swanton; Herbert Hurwitz; David R Spigel; Christopher Sweeney; Howard Burris; Ron Bose; Bongin Yoo; Alisha Stein; Mary Beattie; Razelle Kurzrock
Journal:  J Clin Oncol       Date:  2018-01-10       Impact factor: 44.544

8.  A subgroup cluster-based Bayesian adaptive design for precision medicine.

Authors:  Wentian Guo; Yuan Ji; Daniel V T Catenacci
Journal:  Biometrics       Date:  2016-10-24       Impact factor: 2.571

9.  Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

Authors:  David M Hyman; Igor Puzanov; Vivek Subbiah; Jason E Faris; Ian Chau; Jean-Yves Blay; Jürgen Wolf; Noopur S Raje; Eli L Diamond; Antoine Hollebecque; Radj Gervais; Maria Elena Elez-Fernandez; Antoine Italiano; Ralf-Dieter Hofheinz; Manuel Hidalgo; Emily Chan; Martin Schuler; Susan Frances Lasserre; Martina Makrutzki; Florin Sirzen; Maria Luisa Veronese; Josep Tabernero; José Baselga
Journal:  N Engl J Med       Date:  2015-08-20       Impact factor: 91.245

10.  Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials.

Authors:  Scott M Berry; Kristine R Broglio; Susan Groshen; Donald A Berry
Journal:  Clin Trials       Date:  2013-08-27       Impact factor: 2.486

View more
  4 in total

1.  Borrowing of information across patient subgroups in a basket trial based on distributional discrepancy.

Authors:  Haiyan Zheng; James M S Wason
Journal:  Biostatistics       Date:  2022-01-13       Impact factor: 5.899

2.  Reporting of master protocols towards a standardized approach: A systematic review.

Authors:  Ellie G Siden; Jay Jh Park; Michael J Zoratti; Louis Dron; Ofir Harari; Kristian Thorlund; Edward J Mills
Journal:  Contemp Clin Trials Commun       Date:  2019-07-04

3.  Exploring Heterogeneity in Histology-Independent Technologies and the Implications for Cost-Effectiveness.

Authors:  Peter Murphy; Lindsay Claxton; Robert Hodgson; David Glynn; Lucy Beresford; Matthew Walton; Alexis Llewellyn; Stephen Palmer; Sofia Dias
Journal:  Med Decis Making       Date:  2021-01-13       Impact factor: 2.583

4.  Subgroup-specific dose finding for phase I-II trials using Bayesian clustering.

Authors:  Alexandra Curtis; Brian Smith; Andrew G Chapple
Journal:  Stat Med       Date:  2022-04-16       Impact factor: 2.497

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.